4 active not recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 4 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast Nerandomilast - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Boehringer Ingelheim | 1666 | 2024-09-26 | 2026-10-28 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1057 | 2023-10-25 | 2026-04-23 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1255 | 2023-09-14 | 2026-03-24 |
| Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis Sirolimus - Pulmonary Fibrosis, COVID-19 Pneumonia | Phase 2 / Phase 3 | Active not recruiting | University of Chicago | 60 | 2021-07-09 | 2025-12-15 |
Idiopathic Pulmonary Fibrosis (2) · Arthritis, Rheumatoid (1) · Connective Tissue Diseases (1) · Fibrosis (1) · Lung Diseases, Interstitial (1) · Post-Acute COVID-19 Syndrome (1) · Sarcoidosis (1) · Scleroderma, Diffuse (1)
Lung Diseases (4) · Respiratory Tract Diseases (4) · Lung Diseases, Interstitial (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Fibrosis (2) · Arthritis (1) · Autoimmune Diseases (1) · COVID-19 (1) · Chronic Disease (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Disease Attributes (1) · Hemic and Lymphatic Diseases (1) · Hypersensitivity (1)
BI 1015550 (1) · Sirolimus (1)
Bristol-Myers Squibb (2) · Boehringer Ingelheim (1) · University of Chicago (1)
United States (4) · Argentina (3) · Australia (3) · Austria (3) · Belgium (3) · Brazil (3) · Canada (3) · Chile (3) · China (3) · Denmark (3) · Finland (3) · France (3) · Germany (3) · Greece (3) · Hungary (3)
Ayodeji Adegunsoye, MD, MS (1)
2023 (3)